Project Phase I, open-label, dose-escalation study to investigate the safety of ISTH0036, a ‘next generation’…

Basic data

Title:
Phase I, open-label, dose-escalation study to investigate the safety of ISTH0036, a ‘next generation’ TGF-β2-selective antisense oligonucleotide, in subjects with primary open-angle glaucoma undergoing trabeculectomy
Duration:
21/04/2015 to 31/12/2018
Abstract / short description:
A phase I, open-label, dose-escalation study to investigate the safety of ISTH0036, a ‘next generation’ TGF-β2-selective
antisense oligonucleotide, in subjects with primary open-angle glaucoma undergoing trabeculectomy.
Keywords:
ISTH0036
Glaucoma
Ophthalmologie
Studie Trial

Involved staff

Managers

Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

University Eye Hospital
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Funders

München, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.